Efficacy and Safety of Upadacitinib in Inflammatory Bowel Disease

Launched by XIANG GAO · Jan 13, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the effectiveness and safety of a medication called upadacitinib for patients with Inflammatory Bowel Disease (IBD), which includes conditions like Crohn's Disease and Ulcerative Colitis. Many patients do not respond well to current treatments, so researchers want to see how well this new oral medication works specifically for Chinese patients with IBD. The trial is being conducted at multiple centers and aims to gather real-world data to help doctors make informed decisions about treatment.

To participate in the study, patients must be diagnosed with either ulcerative colitis or Crohn's disease and require upadacitinib treatment as determined by their doctor. They also need to provide consent to join the trial. However, those currently involved in another clinical study or who cannot take upadacitinib for specific medical reasons will not be eligible. Participants can expect to receive the medication and be monitored closely for its effects, contributing valuable information to the understanding of how this treatment works in the Chinese population.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Inclusion criteria were patients of any gender, diagnosed with ulcerative colitis or Crohn's disease according to current guidelines, requiring initial upadacitinib treatment as judged by the treating physician, and providing signed informed consent.
• Exclusion Criteria:
• • Exclusion criteria included current or planned participation in any other clinical study, contraindications to upadacitinib treatment as per the drug's instructions, and patients deemed unsuitable for the study by the researchers.